Cisplatin is a platinum-based chemotherapy drug used against a wide range of malignancies, including cancers of the head and neck, lung, ovary, bladder and testis. Its anticancer activity depends largely on its ability to bind DNA and create platinum–DNA adducts. These lesions distort the DNA double helix and interfere with replication and transcription, ultimately triggering cell death in vulnerable tumor cells. However, cisplatin can also reach the cochlea, the spiral-shaped organ responsible for hearing, where it may accumulate and generate oxidative stress. The resulting injury frequently affects cochlear hair cells, particularly the outer hair cells that amplify sound vibrations and convert them into electrical signals for the brain.

Unlike many tissues, mature mammalian auditory hair cells have little capacity for regeneration. Once these cells are destroyed, the resulting hearing loss is often permanent. Cisplatin-associated ototoxicity can begin with ringing in the ears, difficulty understanding high-frequency sounds and abnormal sensitivity to everyday noise before progressing to broader auditory impairment. The severity of the damage varies among patients and can depend on factors such as cumulative dose, age, genetic background and other medications. Because cisplatin remains highly effective against aggressive cancers, doctors face a difficult balance: protecting the ear without weakening the drug’s ability to destroy malignant cells.

The new research focuses on short-chain fatty acids, or SCFAs, including acetate, propionate and butyrate. These molecules are generated when beneficial intestinal bacteria ferment dietary fiber that the human digestive system cannot fully break down. SCFAs are best known for supporting intestinal health, but they also act as signaling molecules throughout the body. They can influence immune activity, cellular metabolism, mitochondrial function and gene regulation. Some SCFAs interact with cell-surface receptors such as G-protein-coupled receptors, while others enter cells and inhibit enzymes known as histone deacetylases. Through these mechanisms, SCFAs can alter the accessibility of DNA and change the expression of genes involved in inflammation, stress responses and tissue maintenance.

According to the study, SCFAs significantly alleviated the structural and functional damage caused by cisplatin in auditory sensory cells. The investigators linked this protective effect to the preservation of MUTYH expression. MUTYH, whose name derives from “mutY homolog,” is a DNA glycosylase involved in base-excision repair, one of the cell’s major systems for correcting small but potentially dangerous DNA lesions. A central target of MUTYH is an adenine mistakenly paired with 8-oxoguanine, a modified DNA base produced when reactive oxygen species attack guanine. If this mismatch is not corrected, it can generate permanent genetic mutations during DNA replication.

The connection is particularly relevant to cisplatin-induced cochlear injury because oxidative stress is considered a major driver of hair-cell degeneration. Cisplatin can disturb mitochondrial activity, increase the production of reactive oxygen species and activate cellular pathways associated with inflammation and programmed cell death. Oxidized DNA bases may accumulate as a consequence. By maintaining MUTYH expression, SCFAs may help sensory cells recognize and remove specific oxidative DNA lesions before they become more serious forms of genomic damage. The findings therefore suggest that the protective action of SCFAs is not limited to general antioxidant activity; it may also involve preserving the machinery that repairs DNA after oxidative attack.

The study’s implications extend beyond a single protein or one chemotherapy complication. It presents the gut microbiome as a possible regulator of vulnerability in tissues far from the intestine. The bacteria living in the digestive tract differ substantially between individuals, and so does their production of SCFAs. Diet, antibiotic exposure, illness, age and cancer treatment can all reshape microbial communities and alter the amount and composition of metabolites entering circulation. If SCFA availability influences MUTYH expression in the cochlea, differences in the gut microbiome could help explain why some patients experience severe cisplatin-related hearing loss while others retain better auditory function after similar treatment.

At the same time, the findings should not yet be interpreted as proof that eating more fiber, taking a probiotic or using an SCFA supplement can prevent hearing loss in people receiving cisplatin. The study establishes a promising biological relationship, but laboratory protection must be translated carefully into safe clinical strategies. The dose, timing and route of SCFA delivery will matter, as will the question of whether a treatment can protect sensory cells without reducing cisplatin’s anticancer effect. A compound that broadly changes gene expression or immune signaling could have unintended consequences in patients whose tumors and normal tissues are already under intense physiological stress.

Future work will need to determine precisely how SCFAs preserve MUTYH expression and whether that effect depends on a particular receptor, epigenetic pathway or metabolic state. Researchers will also need to test whether MUTYH is required for protection, rather than simply associated with it, by increasing or disabling the protein in controlled experimental systems. Studies in animal models and, eventually, carefully designed clinical trials could reveal whether SCFA-based interventions reduce measurable hearing loss, tinnitus and cochlear injury during chemotherapy. For now, the report offers a striking mechanistic insight: metabolites created by gut bacteria may help defend the inner ear against one of oncology’s most damaging side effects by sustaining a fundamental DNA-repair pathway. That possibility places MUTYH at the center of an emerging strategy to make lifesaving cancer treatment less costly for the senses.

Subject of Research: Protection against cisplatin-induced sensory cell damage and hearing loss through short-chain fatty acids and MUTYH expression.

Article Title: Short-chain fatty acids significantly alleviate cisplatin induced sensory cell damage and hearing loss by maintaining the expression of MUTYH.

Article References: Zhang, ZX., Zhu, YQ., Yan, FX. et al. Short-chain fatty acids significantly alleviate cisplatin induced sensory cell damage and hearing loss by maintaining the expression of MUTYH. Cell Death Discovery. (2026). https://doi.org/10.1038/s41420-026-03283-9

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03283-9

Keywords: cisplatin, hearing loss, ototoxicity, short-chain fatty acids, MUTYH, DNA repair, oxidative stress, cochlear hair cells, gut–ear axis, cancer treatment.

Cisplatin works by forming DNA cross-links leading to apoptosis in rapidly dividing cancer cells, a mechanism that underpins its anticancer properties. However, the collateral damage inflicted on non-cancerous tissue, particularly in reproductive organs, raises significant concerns. Ovarian tissue is particularly vulnerable during chemotherapy, and this susceptibility can lead to long-term reproductive issues and hormonal imbalances. The search for protective agents is, therefore, a pressing need within oncology.

Ulinastatin, a human serum trypsin inhibitor, has garnered interest because of its multifunctional properties, including anti-inflammatory and antioxidant effects. Zhao and colleagues hypothesized that Ulinastatin could leverage these properties to mitigate ovarian damage caused by cisplatin. This hypothesis served as the foundation for their research and subsequent investigations into the underlying mechanisms of action.

The Nrf2/Keap1 signaling pathway plays a pivotal role in cellular defense against oxidative stress. Under normal conditions, Nrf2 is kept in the cytoplasm by Keap1, which marks it for degradation. However, in response to cellular stress, Nrf2 dissociates from Keap1, translocates to the nucleus, and initiates the transcription of various antioxidant genes. The potential for Ulinastatin to activate this pathway offers a plausible explanation for its protective effects against chemotherapy-induced damage.

Zhao et al. meticulously designed their study to assess the protective efficacy of Ulinastatin in a preclinical model. The experimental setup involved administering cisplatin to induce ovarian toxicity, followed by treatment with Ulinastatin. The researchers conducted a series of assessments to evaluate ovarian function, structural integrity, and markers of oxidative stress. Their results were compelling and indicated a considerable reduction in markers of ovarian damage in the Ulinastatin-treated group.

Histological examination further revealed that Ulinastatin treatment preserved ovarian architecture, with a higher number of healthy follicles observed compared to the cisplatin-only group. These findings are significant, as they demonstrate that Ulinastatin not only protects against immediate cellular damage but also sustains the long-term viability of ovarian reserve, which is crucial for fertility.

Moreover, the study articulated the mechanisms through which Ulinastatin exerts its protective effects. By enhancing the expression of Nrf2 and its downstream targets, Ulinastatin effectively shifts the cellular environment towards a more resilient state, equipped to handle the oxidative stress associated with cisplatin treatment. This information holds vital implications for the future of cancer therapies, particularly for female patients facing reproductive challenges post-chemotherapy.

The implications of this research extend beyond mere ovarian protection. By promoting the understanding and potential use of Ulinastatin, Zhao et al. are contributing to a broader narrative of personalized medicine in oncology. As treatments become increasingly targeted and tailored, such protective strategies may significantly enhance the quality of life for cancer survivors, particularly women who face the dual battle of fighting cancer and preserving reproductive health.

In the realm of oncology, the development of supportive therapies that accompany traditional treatments can make substantial differences in patient outcomes. The study’s findings emphasize the importance of considering not only the efficacy of cancer treatments but also their safety profiles and impacts on patient quality of life. This research exemplifies a forward-thinking approach to cancer care, integrating protective strategies into therapeutic protocols.

As further research unfolds, the potential to translate these findings into clinical practice presents an exciting avenue for intervention. The prospect of using Ulinastatin in conjunction with cisplatin awaits validation through clinical trials, where its efficacy and safety can be rigorously tested in human subjects. Such advancements could pave the way for improved treatment regimens that support both cancer control and reproductive health.

In conclusion, the study by Zhao et al. represents a pivotal step toward understanding and mitigating the adverse effects of cisplatin on ovarian health. The evidence supporting Ulinastatin’s protective properties through the Nrf2/Keap1 pathway presents valuable insights for future therapeutic strategies in oncology. As the medical community continues to evolve its approach to cancer treatment, the integration of protective agents such as Ulinastatin could revolutionize the landscape, ensuring that the fight against cancer does not come at the cost of reproductive vitality for women.

This research not only highlights significant scientific advancements but also echoes a growing acknowledgment within the medical field: that the journey through cancer treatment should factor in the holistic needs of patients. Ulinastatin’s promise is just one of the many innovative strategies being developed to safeguard the health of cancer survivors, reflecting a future where oncology care is as compassionate as it is effective.

By forging connections between groundbreaking research and practical applications, Zhao et al. inspire hope for countless patients navigating the complexities of cancer treatment. Their findings mark an essential contribution to the ongoing narrative of advancing cancer therapies that prioritize both survival and quality of life.

Subject of Research:

Article Title: Ulinastatin protects against cisplatin-induced ovarian damage via Nrf2/Keap1 pathway

Article References:

Zhao, L., Wu, Y., Zhang, X. et al. Ulinastatin protects against cisplatin-induced ovarian damage via Nrf2/Keap1 pathway.
J Ovarian Res 18, 207 (2025). https://doi.org/10.1186/s13048-025-01760-w

Image Credits: AI Generated

DOI: 10.1186/s13048-025-01760-w

Keywords: ovarian damage, Ulinastatin, cisplatin, Nrf2/Keap1 pathway, chemotherapy, reproductive health